Abstract: Metabolic syndrome (MetS) is commonly observed among peritoneal dialysis (PD) patients, and hyperbranched polyglycerol (HPG) is a promising glucose-sparing osmotic agent for PD. However, the biocompatibility of a HPG-based PD solution (HPG) in subjects with MetS has not been investigated. This study compared the local and systemic effects of a HPG solution with conventional physioneal (PYS) and icodextrin (ICO) PD solutions in rats with MetS. Obese type 2 diabetic ZSF1 rats received a daily intraperitoneal injection of PD solutions (10 mL) for 3 months. The peritoneal membrane (PM) function was determined by ultrafiltration (UF), and the systemic responses were determined by profiling blood metabolic substances, cytokines and oxidative status. Tissue damage was assessed by histology. At the end of the 3-month treatment with PD solutions, PM damage and UF loss in both the PYS and ICO groups were greater than those in the HPG group. Blood analyses showed that compared to the baseline control, the rats in the HPG group exhibited a significant decrease only in serum albumin and IL-6 and a minor glomerular injury, whereas in both the PYS and ICO groups, there were more significant decreases in serum albumin, antioxidant activity, IL-6, KC/GRO (CXCL1) and TNF-a (in ICO only) as well as a more substantial glomerular injury compared to the HPG group. Furthermore, PYS increased serum creatinine, serum glucose and urine production. In conclusion, compared to PYS or ICO solutions, the HPG solution had less adverse effects locally on the PM and systemically on distant organs (e.g. kidneys) and the plasma oxidative status in rats with MetS.
Metabolic syndrome (MetS) is a collective term used for several metabolic conditions, including obesity, dyslipidaemia, hypertension, insulin resistance and dysglycaemia [1] . MetS is a risk factor for developing chronic kidney disease [2] [3] [4] and has been observed in 40-90% of peritoneal dialysis (PD) patients [5] [6] [7] [8] . During glucose-based PD therapy, 60-80% of glucose in conventional glucose-based PD solutions is absorbed by patients, approximately 100-300 g of glucose per day [9] . Long-term exposure to the high glucose load in the peritoneal cavity of PD patients with MetS is significantly correlated with an increased rate of mortality and PD failure [10] [11] [12] [13] [14] . Therefore, there is an unmet need for glucose-sparing PD therapy which is crucial for treating PD patients with MetS.
Low molecular weight hyperbranched polyglycerol (HPG, 0.5-3 kDa) has recently been tested as a novel osmotic agent in the development of a glucose-sparing PD solution [15] [16] [17] . It has been shown that HPG-based PD solutions induce similar or improved efficacy of fluid removal and reduce the level of peritoneal membrane (PM) damage compared to conventional glucose-based dianeal or physioneal (denoted as PYS) PD solutions in rat models of PD [15] [16] [17] . However, the local and systemic effects of chronic exposure to a HPG-based PD solution under the condition of MetS have not been investigated.
Obese diabetic ZSF1 rats are generated by crossing Zucker diabetic fatty (ZDF) female rats and spontaneously hypertensive heart failure (SHHF) male rats. These obese diabetic rats have a similar set of conditions to MetS in human beings, including ageing-dependent vascular disease or hypertension, type 2 diabetes, hyperlipidaemia and nephropathy [18] [19] [20] [21] [22] . At the age of 41 weeks, male obese ZSF1 rats display severe diabetic nephropathy, elevated blood pressure and additional disease complications, such as hypertension, hypertriglyceridaemia and hypercholesterolaemia [21, 22] . The objective of this study was to examine the effects of a long-term daily intraperitoneal (IP) injection of a HPG-based PD solution on the PM, blood proteins and metabolites, and serum antioxidant capacity as well as its impact on the kidneys in obese diabetic ZSF1 male rats compared to exposure to two clinically approved PD solutions, PYS and icodextrin (denoted as ICO).
Materials and Methods
PD solutions and Animals. PYS (Physioneal TM 40 solution, 2.27% glucose w/v) and ICO (Extraneal TM , 7.5% icodextrin w/v) were purchased from Baxter Healthcare Co. (Deerfield, IL, USA). HPG (1 kDa) was synthesized by an anionic ring opening multibranching Author for correspondence: Caigan Du, Jack Bell Research Centre, 2660 Oak Street, Vancouver, BC, Canada V6H 3Z6 (e-mail: caigan@mail.ubc.ca). polymerization and characterized following our previous reports [15] [16] [17] . A HPG PD solution (denoted as HPG, 6% HPG, approximately 402 mOsmol/kg, pH 7.4) and electrolyte control (denoted as Control, 251 mOsmol/kg, pH 7.4) solutions were prepared as reported previously [15] .
Obese ZSF1 male rats (~300 g body-weight, 8 weeks old) were purchased from Charles River Laboratories International, Inc. (Wilmington, MA, USA) and were F1 hybrids from a cross between female ZDF and male SHHF rats at the vendor facility (Charles River laboratory) [18] . For the experiments, rats were maintained in the animal facility of the Jack Bell Research Centre (Vancouver, BC, Canada) and were used in accordance with the Canadian Council on Animal Care guidelines under the protocols approved by the Animal Use Subcommittee at the University of British Columbia (Vancouver, BC, Canada).
IP injection of PD solutions and body-weight gain. Obese diabetic rats received a once-daily IP injection of 10 mL of the PD solution or Control as previously established in our laboratory [15] . In brief, after anaesthesia with isoflurane, 10 mL of a pre-warmed PD solution (Control, PYS, ICO or HPG) was slowly injected into the peritoneal cavity at the abdominal midline. After awakening, within 1-2 min., animals had free access to food and drinking water. The daily injections were continued for 3 months.
The body-weights of the animals were monitored daily as an indicator of the general health status, and body-weight gain was calculated: % = (BW x À BW 0 )/BW 0 9 100, where BW x is the body-weight on an indicated day and BW 0 is the body-weight on the first day of the treatment. To investigate the impact of different PD solutions on body-weight gain, we compared the differences in body-weight gain between groups using the Control group as the baseline control. Thus, if the body-weight gain in the PD solution groups (PYS, ICO or HPG) was less than that in the Control group (a baseline of the bodyweight gain), then the change was termed reduced body-weight gain (or body-weight loss) in the PD solution group.
Ultrafiltration. After 3 months of daily peritoneal exposure to the PD solutions, the ultrafiltration (UF) of the PM was determined by an IP injection of 30 mL of PYS. After 4 hr of dwelling time, the remaining peritoneal fluid was recovered using a syringe, and its volume was used to calculate the UF capacity.
Histology of the peritoneum and kidneys. After the UF measurement, two strips of parietal peritoneum (one from the left lumbar abdominal region and the other from the right region) and kidney tissues were collected from each rat. All tissues were fixed in 10% neutral-buffered formalin and embedded in paraffin wax. Sections were cut to a 4-lm thickness. The peritoneal tissue sections were stained with haematoxylin and eosin (H&E) and the kidney sections with periodic acid-Schiff (PAS). The stained tissue sections were scanned with a Leica SCN400 Slide scanner (Leica Microsystems Inc., Concord, ON, Canada). Both the submesothelial thickness of the PM and glomerular injury of the kidney were quantitated using a Digital Image Hub -A slidepath Software Solution (Leica Microsystems, Inc.) in two separate tissue sections from each rat in a blinded fashion as described previously [15, 16, 23] .
A semi-quantitative scoring system using a scale from 1 to 4 to determine the severity of mesangial expansion was established based on the percentage of the area stained strongly with PAS, indicating the mesangial expansion in an affected glomerulus: 1 (<24% of the area affected, with dense staining, normal), 2 (25-49%, mild), 3 (50-74%, moderate) and 4 (>75%, severe). A range of 180-250 glomeruli were counted and averaged for each kidney.
Blood metabolic screening. Blood samples were collected from the tail vein using a lithium heparin tube after 3 months of a daily IP Serum antioxidant activity. Serum samples were collected as described above, and the antioxidant activity was determined using two methods -the ferric (Fe 3+ ) reducing ability of plasma (FRAP) [24] and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay [25] .
FRAP measures the iron-chelating ability of serum. In brief, FRAP reagent was first prepared by mixing of 25 mL of 300 mM acetate buffer (pH 3.6), 2.5 mL of 10 mM TPTZ (2,4,6-tris(2-pyridyl)-s-triazine]) and 2.5 mL of 20 mM ferric chloride for 30 min. at 37°C. Serum samples (10 lL in 30 lL water per well) in triplicate from each rat were incubated with 100 lL/well of FRAP reagent in a 96-well plate for 4 min. at RT. The determination of the optical density (OD) was performed at 593 nm using an ELx808 Ultra Microplate Reader (BioTek, Winooski, VT, USA). Different concentrations of ferrous sulphate were used as standards. Data are presented as mM ferrous sulphate equivalents.
Compared to H 2 O as a blank control, the radical scavenging ability of serum was measured using the DPPH assay. In brief, serum samples were diluted with water at a ratio of 1-40 and were incubated with equal amount (50 lL) of a 0.135 mM DPPH solution in the dark for 30 min. at RT. The OD was measured at 517 nm using an ELx808 Ultra Microplate Reader (BioTek). Data are presented as the percentage of DPPH scavenging: % = (OD control À OD serum )/ OD control 9 100, where OD control is the OD value of blank control OD serum is a serum sample.
Serum uric acid assay. The serum level of uric acid was determined using a uric acid kit following manufacturer's protocol (Eton Bioscience, San Diego, CA, USA). In brief, serum samples (50 lL per well) in duplicate from each rat were incubated with the reaction solution (50 lL per well) in a 96-well plate for 30 min. at 37°C. The OD was measured at 570 nm using an EL9808 Ultra Microplate Reader (BioTek), and the level of uric acid was calculated based on the known concentrations of uric acid standards.
Urine collection and kidney function determination. A 24-hr urine sample was collected at the end of 3-month treatment using a metabolic cage, in which the rats had unrestricted access to food and drinking water. The collected urine was immediately centrifuged at 1750 g for 15 min. to remove any food scraps and faecal matter. After its volume was measured, the sample was stored in aliquots at À20°C until all samples were collected for the determination of both the protein and CRE levels at the same time.
The levels of urine CRE were measured in the Chemistry Laboratory at the Vancouver Coastal Health Regional Laboratory Medicine (Vancouver, BC, Canada) using the Dimension Vista â System with CRE2 reagent cartridges (Siemens Healthcare Diagnostics, Inc., Newark, DE, USA). The levels of urine protein were determined using the Bradford Bio-Rad protein assay following the manufacturer's instructions (Bio-Rad Laboratories-Canada, Mississauga, ON, Canada). In brief, the protein in urine (0.3 mL) was precipitated using 10% trichloroacetic acid (TCA), followed by centrifugation at 11,000 g for 10 min. The protein pellet was suspended in 50 lL of a 3% sodium hydroxide solution, and 1 lL of this protein solution was added to 200 lL of Bio-Rad dye (109 dilution). The OD values of the urine protein samples, background control and bovine serum albumin (BSA) standards at 595 nm were measured using an ELx808 Ultra Microplate Reader (BioTek), and the protein concentration (mg/mL) in the urine samples was calculated based on the BSA standard curve. The protein-to-CRE ratio (PCR) was calculated for each rat and reported. The kidney function was estimated using the glomerular filtration rate (GFR), which was calculated based on the CRE clearance as follows: GFR = (UCr 9 V)/SCr, where UCr is the CRE level in urine sample, V is the volume of the 24-hr urine sample, and SCr is the CRE in serum.
Statistical analysis. Statistical analysis of the between-group mean difference was performed by the one-tailed t-test or analysis of variance (ANOVA) using GraphPad Prism software (GraphPad, San Diego, CA, USA). A p value of ≤0.05 was considered significant.
Results
Compared to PYS or ICO, there was more body-weight gain in rats receiving a HPG solution.
As shown in fig. 1 , the body-weight gain in all rats increased in a time-dependent manner during the 3-month experimental period, but rats in the Control group gained the most weight among these four groups at any time-point. Compared to the body-weight gain in rats in the Control group (as a baseline), a reduced body-weight gain was observed in rats receiving hypertonic PD solutions (HPG, PYS or ICO). Furthermore, rats in the PYS group had the largest reduced body-weight gain, followed by rats in the ICO group, and the smallest reduction in body-weight gain was observed in rats in the HPG group. According to two-way ANOVA, the difference (p value) was 0.0036 between the Control and HPG groups and <0.0001 between the Control and ICO or PYS groups. The reduced body-weight in rats in the HPG group was significantly less than that in rats in the ICO group (p = 0.033, two-way ANOVA), particularly during the first 2 months, as well as rats in the PYS group (p < 0.0001, two-way ANOVA). These data suggested that compared to the Control, in obese ZSF1 rats, a daily IP injection of a hypertonic PD solution reduced bodyweight gain, but compared to the ICO or PYS groups, the effect was smallest in the HPG group.
Compared to PYS or ICO, less PM injury was observed in rats receiving a HPG solution. It has been previously reported that compared to PYS, a HPG PD solution causes less PM damage in healthy Wistar rats [15] . In this study, a rat model of MetS was used to investigate the effects of HPG on the PM under MetS. A histological examination of PM tissues was performed after 3 months of repeated exposure to the Control, HPG, PYS or ICO solution. As shown in fig. 2A , compared to the HPG or Control groups, more cellular infiltrates were observed in the PM of the rats that received PYS or ICO. Figure 2B shows a comparison of the thickness of the PM. Treatment with all of the hypertonic PD solutions significantly increased the PM thickness, but at different levels (ICO = PYS > HPG). The PM thickness in the ICO or PYS groups was larger than that in the HPG group (PYS versus ICO, p = 0.1062, PYS versus HPG, p = 0.0659, ICO versus HPG, p = 0.0013, one-tailed t-test). The severity of PM injury in these groups was significantly correlated with the loss of UF, as shown in fig. 2C , which shows that the UF in the PYS, ICO or HPG groups was significantly lower than that in the Control group ( fig. 2C ). Similar to the PM injury data, compared to PYS or ICO, HPG had the smallest effect on UF (PYS versus ICO, p = 0.2495; PYS versus HPG, p = 0.0088; ICO versus HPG, p = 0.0032, one-tailed t-test). These data indicate that compared to PYS or ICO, the alteration of the PM structure induced by repeated IP injections of the HPG solution was less severe.
Compared to PYS or ICO, there were smaller changes in the blood metabolic panel and cytokine profile in rats receiving a HPG solution.
To determine whether chronic exposure to HPG had potential side effects on metabolism as well as the immune or inflammatory response under the condition of MetS, changes to both CMP and the cytokine network in blood were examined after 3 months of a daily IP injection of PD solutions. PD solutions were IP injected daily and were allowed to absorb. Thus, changes in the metabolic and cytokine profiles are indicative of changes in metabolism or the status of the inflammatory response. A comparison of the metabolic panel from different groups of rats is provided in table 1. Compared to the Control groups, PYS decreased the level of ALB (but not the ALB Fig. 1 . Compared to physioneal (PYS) or icodextrin (ICO), rats receiving hyperbranched polyglycerol (HPG) have an increased bodyweight gain. The body-weight of rats in each group (Control: n = 7; PYS: n = 6; ICO: n = 7; and HPG: n = 7) was recorded during a period of 3 months of IP injections. Reduced body-weight gain in the PD solution groups (PYS, ICO or HPG) was observed as the body-weight gain in these groups was less than that in the Control group (the baseline of the body-weight gain). All data are presented as the mean AE standard deviation (S.D.), and differences were compared by two-way ANOVA. Control versus PYS, ICO or HPG: p < 0.05.
(A)/GLOB(G) ratio) and increased both the levels of glucose and CRE. ICO decreased both the ALB (and the A/G ratio) and ALP levels and increased the level of GLOB. HPG only decreased the level of ALB (but not the A/G ratio).
The serum cytokine levels are provided in table 2. Screening the blood cytokine profile showed that compared to the Control group, HPG only decreased the level of IL-6, whereas PYS decreased both the IL-6 and KC/GRO levels and ICO decreased the IL-6, KC/GRO and TNF-a levels (table 2). In addition, although all of the hypertonic PD solutions decreased IL-6, the IL-6 level in the HPG group was higher than that in either the PYS (HPG versus PYS, p = 0.0169) or ICO (HPG versus ICO, p = 0.0125) groups. Taken together, these two comprehensive tests showed that HPG had a smaller impact on the metabolic health status and inflammatory response in rats with MetS.
Compared to PYS or ICO, no attenuation of the serum antioxidant capacity was observed in rats receiving a HPG solution.
The antioxidant system is a defence mechanism against oxidative stress caused by elevated reactive oxygen species (ROS), and ROS are produced by aerobic metabolism in diseased tissues or from macrophage activation as part of the immune system response [26, 27] . To compare the effect of HPG to PYS or ICO on the antioxidant system, both the serum antioxidant activity and uric acid level were determined. As shown in fig. 3A , compared to the Control group, the serum iron-chelating activity measured by FRAP was significantly reduced in both the PYS and ICO groups (Control versus PYS, p = 0.0222; Control versus ICO, p = 0.009), but not in the HPG group (p = 0.1702). These data were confirmed by measuring the radical scavenging activity using DPPH ( fig. 3B) , showing that compared to the Control group both the PYS and ICO groups had lower mean values of serum DPPH-antioxidant activity, and the difference between the Control group and ICO treatment group was significant (p = 0.0258). There was no significant difference between the Control group and HPG solution treatment group.
Uric acid is a major antioxidant in serum [28, 29] . The level of antioxidant activity in each experimental group was evaluated by measuring the serum uric acid level. As indicated in fig. 3C , the mean serum uric levels in the PYS and ICO-treated groups were significantly lower than the level in the Control and HPG- The thickness of the submesothelial layer in each tissue section was measured using the Digital Image Hub software. All data are presented as the mean AE S.D., and the mean difference (p value) between the peritoneal dialysis solution group (PYS, ICO or HPG) and Control group was statistically analysed using the one-tailed t-test. (C) Ultrafiltration as a parameter of peritoneal function in each group. Each rat received an intraperitoneal injection of 30 mL of PYS. After 4 hr of dwell time, the fluid was recovered from the peritoneal cavity using a syringe, and its volume was measured. All data are presented as the mean AE S.D., and the mean difference (p value) between the PD solution group (PYS, ICO or HPG) and Control group was statistically analysed using the one-tailed t-test. *p < 0.05 (versus Control). treated group. (Control versus ICO, p = 0.0472, HPG versus ICO, p = 0.0402). The serum uric acid level in the HPG-treated group was not significantly different from that in the Control group. Taken together, these data suggested that compared to the Control group, a daily IP injection of PYS or ICO induced significant attenuations of the serum antioxidant capacity in rats with MetS, but not in rats receiving HPG.
Compared to PYS or ICO, less kidney injury was observed in rats receiving a HPG solution. Residual renal function (RRF) is important to the health of PD patients because the loss of RRF increases the rates of morbidity, mortality and PD technique failure [30, 31] . Thus, potential adverse effects of HPG on the kidneys were examined in the rat model of MetS. As shown in table 3, a 3-month peritoneal exposure to any of the examined PD solutions (PYS, ICO or HPG) did not affect kidney function in these rats at this age; however, compared to the Control group, PYS increased urine output. A semi-quantitative histological analysis of kidney sections indicated that both PYS-and ICO-treated animals had increased levels of glomerular atrophy (Control versus PYS, p = 0.0005; Control versus ICO, p = 0.0058) and mesangial expansion (Control versus PYS, p < 0.0001; Control versus ICO, p = 0.0003). By contrast, the levels of glomerular injury in the Control and HPG groups were not significantly different (p > 0.05). These data suggested that unlike PYS or ICO, HPG did not further impair the diseased kidneys in rats with MetS.
Discussion
Peritoneal dialysis therapy is an established modality for the management of end-stage renal disease that has many advantages over haemodialysis [32] , and the need for glucosesparing PD solutions has been well documented [33] . Both PYS and ICO are clinically approved PD solutions, and HPG solution is currently undergoing pre-clinical evaluation. Both PYS and HPG PD solutions are hyperosmotic to blood (PYS: 395 mOsm/L; HPG: 402 mOsmol/kg, pH 7.4) [15] . The osmotic agent in PYS is glucose (2.27% w/v) and that in HPG PD solution is HPG (1 kDa, 6% w/v) [15] . ICO is isosmotic (282-286 mOsm/L, pH 5.0-6.0); ICO contains a starchderived, water-soluble glucose polymer (dextrins) (number average molecular weight: 5-6.5 kDa; weight average molecular weight: 13-19 kDa, 7.5% w/v) as the colloid osmotic agent [34] . Due to the differences in chemical composition and osmolarity between these three PD solutions (PYS, HPG and ICO), they may cause different local and systemic effects as well as have different efficacies in the removal of fluid and waste. The local and metabolic effects of PYS and ICO have been reviewed previously [34] . HPG is a synthetic polymer, and there is limited information available on chronic exposure to this molecule in animals [15, 35] . Thus, in this pre-clinical study, we compared the effects of these three PD solutions in obese diabetic ZSF1 rats after chronic exposure for 3 months. Our study was designed so that all of these PD solutions at a volume of 10 mL were absorbed in a period of 24 hr [36] and their effects both locally (in the peritoneum) and systemically could be compared. Our data showed that compared to the PYS and ICO groups, rats in the HPG group experienced more body-weight gain, which was positively correlated with results showing that HPG caused less tissue damage locally in the peritoneum and distantly in the kidneys. Additionally, HPG caused a smaller change in a comprehensive profile of metabolic substances and cytokine network response after 3 months of exposure. All data are presented as the mean AE S.D., and the difference between groups was compared using the one-tailed t-test. PYS, physioneal; ICO, icodextrin; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMY, amylase; BUN, blood urea nitrogen; CRE, creatinine; GLOB, globulin; GLU, glucose; PHOS, phosphate; TBIL, total bilirubin; TP, total protein; A/G ratio, ALB/GLOB ratio.
Glucose is a crystalloid that can induce rapid UF within the first few hours of intraperitoneal dwell and is metabolized into carbon dioxide and water after absorption. However, many clinical disadvantages of long-term exposure to glucose have been documented in both diabetic and non-diabetic PD patients [37] , including local (peritoneal toxicity) and systemic effects (excessive glucose absorption) [38] . Compared to glucose-based PD solutions, the use of ICO is associated with improved glycaemic control in diabetic PD patients [39] [40] [41] and reduced insulin resistance in non-diabetic patients [42] . Our previous pre-clinical studies have used healthy rat models to demonstrate that compared to PYS, HPG causes less damage to the peritoneum when administered either by an IP bolus or 3 months of repeated IP injections [15, 16] . The present study showed that replacing glucose with HPG in a PD solution significantly reduced negative effects on body-weight gain Table 2 . Serum cytokine panel of obese male ZSF1 rats after 3 months of daily intraperitoneal injections of 10 mL of a solution (Control, PYS, ICO or HPG).
Cytokine
Control (n = 7) PYS (n = 6) ICO (n = 7) HPG (n = 7) Multiplex cytokine assay kit (Meso Scale Diagnostics, Rockville, MA, USA) was used to measure serum levels of a panel of nine cytokines (IFNc, IL-1b, IL-4, IL-5, IL-6, IL-10, IL-13, KC/GRO and TNF-a) in these rats. The level of each cytokine in each rat was determined by the average of duplicate measurements, and zero represents an undetectable level. Only 1-3 rats in each group had detectable IFN-c or IL-1b in serum samples (data not shown). All data are presented as the mean AE S.D., and the difference between groups was compared using the one-tailed t-test. IL-6: At the end of the 3-month treatment, serum samples were taken from rats (Control: n = 7; PYS: n = 6; ICO: n = 7; and HPG: n = 7). The antioxidant activity of each serum sample was determined using two different standard methods following their standard protocols. (A) Ferric reducing ability of plasma assay. This assay was performed based on the ability of serum to reduce the ferric level.
The activity of each sample/rat is presented as the mean of three separate measurements. (B) a, a-Diphenyl-b-picrylhydrazyl (DPPH) free radical scavenging assay. The DPPH assay measures radical scavenging activity (%) of a serum sample, as the DPPH radical accepts hydrogen. The activity of each sample/rat is presented as the mean of three separate measurements. (C) Uric acid in serum samples. The uric acid level in each serum sample/rat was measured using a commercial uric acid assay kit and is presented as the mean of two separate measurements. The difference (p value) of the mean between the peritoneal dialysis solution group (PYS, ICO or HPG) and Control group was statistically analysed using the onetailed t-test. *p < 0.05 (versus Control).
in rats with MetS compared to the baseline body-weight in the Control group, as indicated by less reduced body-weight gain ( fig. 1 ). HPG better protects the peritoneum ( fig. 2) , which might benefit the long-term preservation of PM activity and UF. In addition, daily absorption of 10 mL of PYS (0.227 g glucose) significantly increased the serum glucose level in the diabetic rats (table 1) , possibly inducing an increase in urine production due to hyperfiltration (table 3) [43] . No increase in the serum glucose level or urine production was observed in the HPG and ICO-treated groups. Taken together, these data indicate that HPG may offer superior protection of the PM structure and function under MetS. In addition, HPG may offer the same or similar benefits of glycaemic control and insulin response, as seen with ICO; however, this result requires further investigation. In all of our experimental groups (PYS, ICO and HPG), compared with the body-weight gain (at baseline) in the Control group, less body-weight gain was observed ( fig. 1 ). Bodyweight gain depends on caloric intake if all rats burned an equal amount of calories due to daily activity in the cage, which implies that less body-weight gain may be caused by a smaller calorie intake; however, we did not specifically investigate this possibility in this study. We also observed that compared to that in the Control group, the serum ALB levels in the experimental groups were decreased and lower in PYS or ICO than in HPG (table 1) . In general, a low ALB level is considered to be an indication of hepatic/renal damage, while a high GLOB level or low A/G ratio is associated with chronic inflammation [44, 45] , suggesting that the reduced body-weight gain in the PYS or ICO group might be caused by the reduced calorie intake due to the presence of relatively higher levels of chronic inflammation in these rats. This hypothesis is also supported by the histology data showing that compared to the HPG group, there were higher levels of glomerular and peritoneal damage in the PYS and ICO groups (figs 2 and 4).
In the present study, a multiplex cytokine assay showed that compared to the Control group, all three PD solutions (PYS, ICO and HPG) induced a decrease in serum IL-6, similar to ALB (table 1) , and a lower KC/GRO ratio (CXCL1) was observed in both the PYS and ICO groups as well as a lower TNF-a level in the ICO group (table 2). These data indicate that different PD solutions (HPS versus PYS or ICO) stimulate different levels of serum cytokine response in the following order from high to low: ICO > PYS > HPG. The complicated biological functions of IL-6, KC/GRO and TNF-a have been well documented in the literature. IL-6 can act as either a proinflammatory cytokine or anti-inflammatory myokine [46] ; KC/GRO is involved not only in the inflammatory responses [47] but also in both the anti-inflammatory response [48] and wound healing [49] ; and TNF-a is a multifunctional cytokine that is involved in a wide spectrum of biological processes, including cell proliferation and differentiation and cell death [50] . Thus, the significance of the decreased serum IL-6, KO/ GRO and TNF-a levels in rats receiving PD solutions in comparison with an electrolyte solution is currently unknown. Because the changes of the IL-6, KC/GRO and TNF-a (ICO > PYS > HPG) levels were correlated with the severity of PM and glomerular injury, it is reasonably suggested that these three cytokines may be part of a feedback cytoprotective mechanism to PD-induced chronic inflammation in this animal model.
In addition to the serum cytokine profile, the change in the antioxidant capacity of plasma is related to MetS [28, 51] . Many serum molecules contribute to the serum antioxidant activity, and uric acid is one of the major antioxidants of serum antioxidant activity with MetS [28, 29] . In the present study, the level of serum antioxidant activity ( fig. 3 ) was negatively correlated with the severity of injuries in both the peritoneum and kidney/glomeruli (figs. 2 and 4). We showed that compared to HPG, both the PYS and ICO treatments resulted in increased levels of renal and peritoneal damage and a lower level of serum antioxidant activity. Additionally, among these experimental groups, the ICO group had the lowest level of both antioxidant activity and uric acid ( fig. 3 ). These data suggest that the decreased antioxidant activity and uric acid levels in the plasma may be part of a pathological cascade that mediates local and distant tissue injuries induced by daily IP injections of a PD solution.
The primary outcome of this study was to evaluate the safety of a HPG-based PD solution using a rat model of MetS. There are several limitations of this study that should be discussed. Firstly, MetS is a term that describes a cluster of metabolic conditions, including insulin resistance, hyperglycaemia, obesity, hypertriglyceridaemia or hypobetalipoproteinaemia and hypertension [52] , but we were only able to examine a Table 3 . Urine parameters of the kidney function of obese male ZSF1 rats after 3 months of daily intraperitoneal injections of 10 mL of a solution (Control, PYS, ICO or HPG).
Measures of 24-hr urine samples
Control (n = 7) PYS (n = 6) ICO (n = 7) HPG (n = 7) All data are presented as the mean AE S.D., and the difference between groups was compared using the one-tailed t-test. PYS, physioneal; ICO, icodextrin; GFR, glomerular filtration rate; PCR, protein/creatinine ratio.
limited number of PD-related consequences: PM injury, metabolic alteration, immune or inflammatory response, the oxidative stress level and kidney function/injury. Secondly, this study was performed on a single strain of rats with a limited number in each group. Therefore, the results may only apply to this given strain with the particular disease type found in this rat model, and the conclusion may be different with larger numbers of animals. Further studies of the safety of HPG are needed, such as in other experimental models with robust statistics of a large sample size. Thirdly, due to the relatively short duration of this study, our results may not represent all of the chronological changes of the PM and kidneys in patients, especially because the loss of RRF is often seen only after a long duration of PD. Finally, the exact molecular mechanisms by which glucose, ICO and HPG exert their different biological effects have not yet been determined.
In conclusion, PD is a well-established renal replacement therapy for ESRD patients, and both PYS and ICO are widely used as conventional PD solutions in clinics. We have previously demonstrated a pre-clinical proof of concept of using HPG as an alternative osmotic agent for PD [15] [16] [17] , and in the present study, we compared the safety profile of HPG with those of PYS and ICO in rats with MetS. After 3 months of daily IP injections, HPG better preserved the structures and functions of the PM and kidneys and compared to the conventional PYS or ICO treatments had less impact on metabolism, the immune response and serum antioxidant capacity. These results suggest that HPG-based PD solutions may produce a favourable safety profile with regard to both local (peritoneal viability) and systemic effects (e.g. lower level of inflammation and lower risk of damage in distant organs) and highlight promising avenues for future studies. 
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